{"id":"n_vwgso7qfsbcd4fob4rga","seq":10916499,"kind":"article","title":"Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer","url":"https://www.timesargus.com/news/business/perioperative-imfinzi-durvalumab-approved-in-the-us-in-novel-regimen-with-neoadjuvant-enfortumab-vedotin-ejfv/article_f3dcea46-595d-595c-8090-0ad71943ef2d.html","summary":"WILMINGTON, Del.--(BUSINESS WIRE)--Nov 13, 2026--","published":"2026-11-13T23:40:05Z","seen":"2026-11-14T00:14:02Z","lang":"en","country":"US","source":{"id":"kite-timesargus-com-f2ab3d","name":"timesargus.com","domain":"timesargus.com"},"via":"kite-timesargus-com-f2ab3d","topics":["vermont"],"authors":["Business Wire"],"story":"st_gxlyph6yblx23rm3m2eq","category":"health","category_p":0.51,"sentiment":"neutral","tone":0.13,"political":0.18}